Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 29, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides

Opportunity for Iopofosine Expansion Within Areas of High Unmet Need in Non-Hodgkin’s Lymphoma Establishes Partnership With One of the Largest Cancer Research and Treatment Organizations in the U.S. ...
May 14, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update

Management to host a conference call today at 8:30 am ET WM pivotal study data to be announced in June FLORHAM PARK, N.J., May 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ:...
May 08, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day

FLORHAM PARK, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
May 07, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024

FLORHAM PARK, N.J., May 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
March 27, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update

FLORHAM PARK, N.J., March 27, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
March 20, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences to Announce 2023 Year End Earnings Results and Host a Conference Call on Wednesday, March 27, 2024

FLORHAM PARK, N.J., March 20, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
March 14, 2024 08:52 ET | Source: Cellectar Biosciences

Cellectar Biosciences to Present at the 36th Annual Roth Conference

FLORHAM PARK, N.J., March 14, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
March 04, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences Reports High Rate of Complete Remission in Investigator Initiated Phase I Study of Iopofosine in Combination with External Beam Radiotherapy in Recurrent Head and Neck Cancer

Complete Remission rate of 64% and Overall Response Rate of 73% demonstrated in highly refractory patients Durability of clinical activity achieved 67% Overall Survival and 42% Progression Free...
February 07, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

FLORHAM PARK, N.J., Feb. 07, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development, and...
January 30, 2024 06:40 ET | Source: Cellectar Biosciences

Cellectar Biosciences Announces Enrollment of the First Patient in Pediatric High-Grade Gliomas Phase 1b Clinical Study

FLORHAM PARK, N.J., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and...